Combined Effects of Testosterone and Estradici on Rat Ventral Prostrate in Organ Culture1

Total Page:16

File Type:pdf, Size:1020Kb

Combined Effects of Testosterone and Estradici on Rat Ventral Prostrate in Organ Culture1 [CANCER RESEARCH 38. 4126-4134, November 1978] 0008-5472/78/0038-OOOOS02.00 Combined Effects of Testosterone and Estradici on Rat Ventral Prostrate in Organ Culture1 ThérèseFeyel-Cabanes, Jean Secchi, Paul Rebel, and Etienne-Emile Baulieu UnitédeRecherche sur le MétabolismeMoléculaire,et la Physio-Pathologie des Stéroides,de l'Institut National de la Santéetde la Recherche Médicale (U 33 Inserm) and ER 125 du CNRS, Hôpitalde Bicétre,78 rue du GénéralLedere.94270 Bicêtre, France ¡T.F-C., P. R., E-E. B.¡,and Roussel-Uclaf, 102 route de Noisy, b.p. n. 9, 93230 Romainvil/e, France [J. S.] Abstract increases, the present studies may prove to be of interest for the study of benign prostatic hypertrophy (14). Explants of ventral prostate from normal 7- to 8-week- old Wistar rats were cultured for 144 hr ¡nthepresence of testosterone (1 nMto 1 /UM)and/or estradici (1 nMto 1 ¿<M).Materials and Methods Several experiments with prostates from different animals Chemicals. Estradiol, testosterone, and diethylstilbestrol were performed at each hormone concentration. Mor were obtained from Roussel-Uclaf, Romainville, France, phology was assessed by light and electron microscopy. and tamoxifen was from International Chemical Industries, In the absence of hormone, the prostatic epithelium Macclesfield, England. Medium 199 was from Flow Labora regressed and the nonepithelial components increased. tories, Ltd., Irvine, Scotland. The latter included the perialveolar sheath of smooth Animals. Male Wistar rats were obtained from Iffa Credo, muscular cells and the interstitial stroma with many fibro- St. Germain sur l'Arbresle, France, and sacrificed at 7 to 8 blasts, active macrophages, and a thick network of colla weeks of age. gen. The presence of estradiol (1 nM to 10 /¿M)didnot Organ Culture. Expiants of ventral prostate were cultured change this picture, whereas testosterone (1 to 100 nM) in serum-free medium as previously described (2). After a maintained the epithelial cells and prevented the increase 24-hr preincubation in hormone-free medium (to eliminate of the perialveolar sheath and interstitial stroma so that any interference by endogenous hormones), the expiants the histológica! picture was like that observed in the were transferred into medium containing estradiol and/or young intact adult animal. Any concentration of estradiol testosterone. Hormones were added to the medium ¡n (1 RMto 1 IJ>M)associated with a physiological concentra propylene glycol. Control cultures in hormone-free medium tion of testosterone (1 to 4 nM) counteracted the andro- received an equal volume of propylene glycol. After 72 hr gen-induced inhibition of the stroma, so that both epithe all expiants were transferred into similar, fresh media for a lium and stroma were simultaneously developed. How further 72 hr. For each treatment examined a minimum of ever, when combined with supraphysiological concentra 10 expiants from different animals were cultured. tions of testosterone (10 to 100 nM), estradiol was no Light Microscopy. Expiants were fixed in Bouin's longer effective and the stroma remained minimal. The aqueous fixative, cut into 5-/um sections, and stained with distribution of mucopolysaccharides and alkaline phos- either hematoxylin-eosin or Papamiltiadès trichrome (23). phatase correlated well with the morphological observa Electron Microscopy. Expiants were fixed in 1% osmic tions. acid in Millonig's buffer for 1 hr atO°,dehydrated in alcohol, The ratio of estradiol to testosterone is therefore insuf and embedded in Epon. Ultrathin sections were treated ficient to explain whether or not interstitial tissue will with 5% uranyl acetate and lead nitrate and were examined develop and a critical factor appears to be the absolute with a Siemens Elmiskop 101 electron microscope. concentration of testosterone. Preliminary observations Expiants fixed in Bouin's aqueous fixative were cut and have indicated that diethylstilbestrol does not mimic es stained with Periodic acid-Schiff to reveal the mucopoly tradiol action and that tamoxifen is neither an agonist nor saccharides. For evaluation of alkaline phosphatase ac an antagonist of the estradiol effect. Accordingly, the cording to Gomori (12), expiants were fixed in 80°alcohol at estradiol effect obtained at physiological concentrations 0°. of testosterone does not seem to be mediated through active participation of a classical estradiol receptor. Results Different concentrations of testosterone and/or estradiol Introduction were tested (Table 1). Light and electron microscopy pic As part of our studies on hormone effects on rat ventral tures were obtained under 6 typical hormonal situations: (a) prostate in organ culture (2), we have been interested in the the situation in the young adult intact animal, where pre activities of estrogens in conjunction with androgen action. sumably testosterone plays the major role (controls); (ft) Some observations in in vitro systems have already been culture with no hormone; (c) culture with testosterone published (10, 18, 19). Since it is known that in the aging alone; (d) culture with estradiol alone; (e) culture with the human the ratio of circulating estradiol to testosterone association of physiological concentrations of testosterone and estradiol; or (f) culture with the association of supra- 1 Presented at the John E. Fogarty International Center Conference on physiological concentrations of testosterone and estradiol Hormonesand Cancer. March 29 to 31. 1978. Bethesda. Md. (Figs. 1 and 2). 4126 CANCER RESEARCH VOL. 38 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1978 American Association for Cancer Research. Testosterone and Estradiol Effects on Rat Ventral Prostate Table 1 sponded to the presence of estradiol. In all cases, periodic Effects of testosterone and/or estradiol on rat ventral prostate acid-Schiff and alkaline phosphatase reactions were mainly epithelium and stroma cells in organ culture found in the stimulated cells. Symbols apply to the images obtained by Jight and electron Preliminary investigations were made with diethylstilbes- microscopy and to the distribution of mucopolysaccharides and trol, a nonsteroidal estrogen (0.1 nM to 1 /¿M).aloneor with alkaline phosphatase, as seen in Figs. 1, 2, and 3 and in the text. 4 nM of testosterone. The effect of diethylstilbestrol alone Epithe Stroma'' lium" did not differ from that of estradiol alone, but when diethyl stilbestrol was combined with a physiological concentra Intact animal tion of testosterone there was no antagonistic effect of the androgen-dependent inhibition of the stromal development, Culture No hormone thus showing no estradiol-like activity in the prostate. Testosterone (1-100 nM) Tamoxifen, an antiestrogen with mixed estrogenic ago Estradiol (1 nw-1 /*M) nist and antagonist activity on the rat uterus (13) and purely Testosterone (1 nM) + estradiol (10 nw); Testosterone (4 nM) + estradiol antagonist activity in the chick oviduct (27), was used alone (1 nM-1 /xM) (1 to 100 nM), in the presence of testosterone (1 nM) or of Testosterone (10 nM) + estradiol (1-10 estradiol (1 to 10 nM), and in the presence of both testoster nw); testosterone (100 nw) + one (4 nM) and estradiol (1 to 10 nM). Tamoxifen showed no estradiol (10-100 nM); testosterone effect on its own and did not modify the effects of testoster (1 ¿IM)+estradiol (1 ¡J.M) " + + + + , maintained as in intact animals; ¿,regressed. one and estradiol when used separately or in combination. * ±,poorly developed as in intact animals; + + + + , developed as These last results indicate a lack of antiestradiol activity in in the absence of hormones. this system. At all concentrations of testosterone >1 nM, the prostatic Discussion expiants were maintained in a state comparable to that The effects of estradiol. alone or associated with testos observed before culture, confirming preceding observa terone, have been studied in seminal vesicles and prostate tions (2). The glandular epithelium was well developed, in several species. These in vivo observations have been with tall columnar cells showing microvilli and signs of difficult to interpret due to complex indirect hormonal active secretory activity (Fig. 3). The perialveolar sheath changes. However, such hormone treatments of castrated was composed of 1 or 2 layers of smooth muscular cells or prepubertal animals (4, 6, 7,11,15,17, 20, 22, 24, 25, 28, and of fibroblasts (9). The interalveolar stroma was reduced 30) caused an increase of the muscular and stromal com to a few dispersed fibroblasts and macrophages. Periodic ponents of the accessory sexual glands. The present in acid-Schiff and alkaline phosphatase staining predomi vitro experiments essentially confirm the observations in nated in the epithelial cells (8). vivo. The use of organ culture in a completely hormone- In the absence of testosterone, the alveolar diameter was deprived medium allowed it to operate at known concentra reduced, the epithelium was atrophied, and its cells were tions of both hormones and to exclude extra prostatic flattened, with the disappearance of secretory granules and changes. microvilli. In addition, they exhibited dense bodies. In The effects of testosterone on ventral prostate can be contrast, the perialveolar sheath was thickened; retracted reproduced partially in an in vitro culture system (2). In the muscular cells showed 'holly-leaf" spines and signs of absence of hormone, the regression observed is similar to micropinocytosis. Moreover, the stroma was well devel that after castration. The mechanism for the striking in oped, with many fibroblasts and active macrophages readily crease of smooth muscle cells, fibroblasts, and other visible together with a dense network of collagen fibers stroma cells in culture without testosterone, whether estra (Fig. 2b). Periodic acid-Schiff and alkaline phosphatase diol is present or not, is unknown. Testosterone can appar stains were again predominant in active cells, this time in ently repress this increase when present at physiological the stroma. concentrations but cannot do so when estradiol is present Regardless of the concentration used, estradiol alone did at the same time.
Recommended publications
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Properties and Units in the Clinical Laboratory Sciences Part X
    Pure Appl. Chem., Vol. 72, No. 5, pp. 747–972, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART X. PROPERTIES AND UNITS IN GENERAL CLINICAL CHEMISTRY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, INGE IBSEN1, IVAN BRUUNSHUUS1, DESMOND KENNY2, RENÉ DYBKÆR3, XAVIER FUENTES-ARDERIU4, GILBERT HILL5, PEDRO SOARES DE ARAUJO6, AND CLEM McDONALD7 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Dublin, Ireland; 3Dept. of Standardisation in Laboratory Medicine, Kommunehospitalet, Copenhagen, Denmark; 4Dept. of Clinical Biochemistry, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain; 5Dept. of Clinical Chemistry, Hospital for Sick Children, Toronto, Canada; 6Dept. of Biochemistry, IQUSP, São Paolo, Brazil; 7Regenstrief Inst. for Health Care, Indiana University School of Medicine, Indianapolis, Indiana, USA #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994 to 1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996). Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada; 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H.
    [Show full text]
  • Anti-Doping Manual Revised Dec. 2018
    PGA TOUR Anti-Doping Program Manual REVISED DECEMBER 2018 Table of Contents How To Use This Manual .......................................................................................................................................................2 SECTION 1: Player Guide To Anti-Doping ...........................................................................................................................3 Who is covered by the Anti-Doping Program .........................................................................................................3 What substances and methods are banned ..........................................................................................................3 Am I liable for a prohibited substance in my body even if I did not intend to take the substance ........................3 What should players know about nutritional and health products ...................................................................3 Are there supplements that have been tested/certified as free from banned substances ........................3 What about medical treatment.................................................................................................................................4 What medications are permitted .............................................................................................................................4 Who conducts the testing and who will be tested ................................................................................................4 What are the steps in
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Spironolactone and XPB: an Old Drug with a New Molecular Target
    biomolecules Review Spironolactone and XPB: An Old Drug with a New Molecular Target Ryan D. Gabbard y , Robert R. Hoopes y and Michael G. Kemp * Department of Pharmacology and Toxicology, Wright State University Boonshoft School of Medicine, Dayton, OH 45435, USA; [email protected] (R.D.G.); [email protected] (R.R.H.) * Correspondence: [email protected]; Tel.: +1-937-775-3823 Contributed equally to this work. y Received: 24 April 2020; Accepted: 10 May 2020; Published: 13 May 2020 Abstract: Spironolactone (SP) is commonly used for the treatment of heart failure, hypertension, and complications of cirrhosis by antagonizing the mineralocorticoid receptor. However, SP also antagonizes the androgen receptor, and thus SP has also been shown to be effective in the treatment of acne, hair loss, and hirsutism in women. Interestingly, recent drug repurposing screens have identified new and diverse functions for SP as a simulator of tumor immunosurveillance and as an inhibitor of DNA repair and viral infection. These novel pharmacological effects of SP have all been linked to the ability of SP to induce the rapid proteolytic degradation of the xeroderma pigmentosum group B (XPB) protein. XPB is a critical enzymatic component of the multi-subunit complex known as transcription factor II-H (TFIIH), which plays essential roles in both DNA repair and the initiation of transcription. Given the critical functions for XPB and TFIIH in these processes, the loss of XPB by SP could lead to mutagenesis. However, the ability of SP to promote cancer stem cell death and facilitate immune recognition may counteract the negative consequences of SP to mitigate carcinogenic risk.
    [Show full text]
  • Pros and Cons Controversy on Molecular Imaging and Dynamic
    Open Access Archives of Biotechnology and Biomedicine Research Article Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- ISSN Standard DNA/RNA of Human Preserving 2639-6777 Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Address for Correspondence: Dr. Alireza Abstract Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, In the current study, we have investigated pros and cons controversy on molecular imaging and dynamics USA, Email: of double-standard DNA/RNA of human preserving stem cells-binding Nano molecules with Androgens/ [email protected]; Anabolic Steroids (AAS) or Testosterone derivatives through tracking of Helium-4 nucleus (Alpha particle) using [email protected] synchrotron radiation. In this regard, the enzymatic oxidation of double-standard DNA/RNA of human preserving Submitted: 31 October 2017 stem cells-binding Nano molecules by haem peroxidases (or heme peroxidases) such as Horseradish Peroxidase Approved: 13 November 2017 (HPR), Chloroperoxidase (CPO), Lactoperoxidase (LPO) and Lignin Peroxidase (LiP) is an important process from Published: 15 November 2017 both the synthetic and mechanistic point of view. Copyright: 2017 Heidari A. This is an open access article distributed under the Creative
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • The Estimation of Melting Points and Fusion Enthalpies Using Experimental Solubilities, Estimated Total Phase Change Entropies, and Mobile Order and Disorder Theory
    The Estimation of Melting Points and Fusion Enthalpies Using Experimental Solubilities, Estimated Total Phase Change Entropies, and Mobile Order and Disorder Theory James S. Chickos* and Gary Nichols Department of Chemistry, University of MissourisSt. Louis, St. Louis, Missouri 63121 Paul Ruelle† Institut d’Analyse Pharmaceutique, Section de Pharmacie, Universite´ de Lausanne, BEP, CH-1015, Lausanne, Switzerland Received October 24, 2001 Melting points and fusion enthalpies are predicted for a series of 81 compounds by combining experimental solubilities in a variety of solvents and analyzed according to the theory of mobile order and disorder (MOD) and using the total phase change entropy estimated by a group additivity method. The error associated in predicting melting points is dependent on the magnitude of the temperature predicted. An error of ( 12 K (( 1 σ) was obtained for compounds melting between ambient temperature and 350 K (24 entries). This error increased to ( 23 K when the temperature range was expanded to 400 K (46 entries) and ( 39 K for the temperature range 298-555 K (79 entries). Fusion enthalpies were predicted within ( 2σ of the experimental values (( 6.4 kJ mol-1) for 79 entries. The uncertainty in the fusion enthalpy did not appear dependent on the magnitude of the melting point. Two outliers, adamantane and camphor, have significant phase transitions that occur below room temperature. Estimates of melting temperature and fusion enthalpy for these compounds were characterized by significantly larger errors. INTRODUCTION of Mobile Order and Disorder Theory (MOD). In this pub- Melting points and enthalpies of fusion are important and lication, we would like to report the results of a study in useful thermochemical properties.
    [Show full text]
  • LPGA Prohibited Substances List
    LPGA PROHIBITED SUBSTANCE CLASSES AND PROHIBITED METHODS - 2019 Norethandrolone; Oxabolone; PROHIBITED SUBSTANCES Oxandrolone; Oxymesterone; 1. NON-APPROVED SUBSTANCES: Any Oxymetholone pharmacological substance which is not addressed by any of the Prostanozol(17β-[(tetrahydropyran-2-yl)oxy]-1'H- subsequent sections of the Prohibited List and with no current pyrazolo[3,4:2,3]-5α-androstane); approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical Quinbolone; development or discontinued, designer drugs, substances Stanozolol; approved only for veterinary use) is prohibited at all times. Stenbolone; 2. ANABOLIC AGENTS: Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna- 4,9,11-trien-3-one); 1. Anabolic Androgenic Steroids (AAS) Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); a. Exogenous1 AAS, including: And other substances with a similar chemical structure or similar biological effect(s). 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 2 1-Androstenedione (5α-androst-1-ene-3,17-dione); b. Endogenous AAS when administered exogenously: 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 19-Norandrostenediol (estr-4-ene-3,17-diol); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 19-Norandrostenedione (estr-4-ene-3,17-dione); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); Androstanolone (5α-dihydrotestosterone,17β-hydroxy-5α- androstan-3-one); Bolandiol (estr-4-ene-3β,17β-diol); Androstenediol (androst-5-ene-3β,17β-diol); Bolasterone; Androstenedione
    [Show full text]